How about the combination of temozolomide and cisplatin in the treatment of malignant melanoma?

The combination of temozolomide and cisplatin has shown certain efficacy in the treatment of malignant melanoma (melanoma), especially in the adjuvant treatment of mucosal melanoma.

Multiple studies have shown that temozolomide combined with cisplatin can significantly improve the recurrence-free survival (RFS), distant metastasis-free survival (DMFS) and overall survival (OS) of patients with adenocarcinoma. For example, in a study by Professor Guo Jun's team, patients with adenocarcinoma who received temozolomide combined with cisplatin chemotherapy showed longer RFS, DMFS and OS compared with toripalimab (anti-PD-1). Specifically, the median RFS was 28.2 months, and DMFS was 42.0 months, and OS reached 93.4 months, both significantly better than the toripalimab group.

Temozolomide combined with cisplatin is mainly suitable for adjuvant treatment of mucosal melanoma. There are significant differences in biological characteristics and treatment responses between mucosal melanoma and cutaneous melanoma, so the selection of treatment options should also be different. For patients with mucosal melanoma, this program can provide a more effective treatment option.

Although both temozolomide and cisplatin have certain side effects, such as bone marrow suppression, gastrointestinal reactions, liver and kidney function damage, etc., these side effects can usually be effectively controlled through reasonable dose adjustment, supportive treatment, and symptomatic treatment. Doctors will develop a personalized treatment plan based on the patient's specific situation, and closely monitor the patient's physical condition and adverse reactions during the treatment process to ensure the safety and effectiveness of the treatment.